Martie Jackson
Primary Care · Brandon, FLNPI 1891753166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 34.9% of the total. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$819
- Gilead$555
- Sanofi$483
- Bristol Myers Squibb$438
- Takeda Pharmaceuticals U.S.A., Inc.$398
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,51499%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $2,642 |
| Johnson & Johnson | 35 | $819 |
| Gilead | 23 | $555 |
| Sanofi | 16 | $483 |
| Bristol Myers Squibb | 29 | $438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $398 |
| Pfizer | 18 | $285 |
| Madrigal Pharmaceuticals | 9 | $242 |
| Intercept Pharmaceuticals, Inc. | 11 | $232 |
| Celltrion USA Inc. | 6 | $194 |
| Phathom Pharmaceuticals, Inc. | 4 | $190 |
| Ardelyx, Inc. | 9 | $163 |
| Vivus LLC | 4 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $88 |
| Lilly USA, LLC | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Aimmune Therapeutics, Inc. | 4 | $73 |
| Redhill Biopharma Inc. | 3 | $68 |
| Mirum Pharmaceuticals, Inc. | 2 | $60 |
| Exact Sciences | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $51 |
| Novo Nordisk | 2 | $51 |
| Ironwood Pharmaceuticals, Inc | 2 | $43 |
| Braintree Laboratories, Inc. | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Merck | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,581 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HumiraAdalimumab | 14 | $94,231 |
| Mesalamine | 19 | $9,341 |
| Colestipol Hcl | 29 | $2,551 |
| Dicyclomine Hcl | 70 | $1,322 |
| Sucralfate | 41 | $1,138 |
| Budesonide DrBudesonide | 11 | $916 |
| Pantoprazole Sodium | 139 | $888 |
| Omeprazole | 70 | $850 |
| Sulfasalazine | 22 | $760 |
| Famotidine | 54 | $605 |
| Esomeprazole Magnesium | 19 | $536 |
| Ondansetron OdtOndansetron | 11 | $238 |
| Ondansetron Hcl | 19 | $175 |
| Metronidazole | 15 | $144 |
| Promethazine Hcl | 16 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira | $2,642 | $94,23114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Brandon
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
- Robert PerriPalm Coast$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.